BR112013003989A2 - características e propriedades citolíticas de células expressando th1 - Google Patents

características e propriedades citolíticas de células expressando th1

Info

Publication number
BR112013003989A2
BR112013003989A2 BR112013003989A BR112013003989A BR112013003989A2 BR 112013003989 A2 BR112013003989 A2 BR 112013003989A2 BR 112013003989 A BR112013003989 A BR 112013003989A BR 112013003989 A BR112013003989 A BR 112013003989A BR 112013003989 A2 BR112013003989 A2 BR 112013003989A2
Authority
BR
Brazil
Prior art keywords
cells
cytolytic
killer
cytolytic activity
properties
Prior art date
Application number
BR112013003989A
Other languages
English (en)
Other versions
BR112013003989B1 (pt
Inventor
Har-Noy Michael
Original Assignee
Immunovative Therapies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovative Therapies Ltd filed Critical Immunovative Therapies Ltd
Publication of BR112013003989A2 publication Critical patent/BR112013003989A2/pt
Publication of BR112013003989B1 publication Critical patent/BR112013003989B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

características e propriedades citolíticas de células expressando th1. a presente invenção refere-se a um novo tipo celular que foi gerado que tem tanto características de th1 como atividade citolítica. estas células th1/assassinas são células cd4+ purificadas do sangue periférico e manipuladas para ter características de th1 como produção de ifn-gama combinada com a atividade citolítica similar a células t citotóxicas (ctl). a atividade de ctl é direcionada a células doentes, não células normais. a atividade citolíca das células th1/assassinas é mediada pelo mecanismo de granzima b-perforina e resulta na morte apoptótica de células doentes. os métodos de produção e utilização destas células th1/assassinas incluem o isolamento de células cd4+ do sangue periférico, ativação das células t cd4+ para formar células th1/assassinas e administração destas células th1/assassinas com atividade citolítica a um paciente em que as células th1/assassinas são alogeneicas ao paciente.
BR112013003989-2A 2010-08-20 2011-08-22 composição compreendendo células cd4+ th1/assassinas e método in vitro para destruir células cancerosas, células infectadas ou combinações das mesmas BR112013003989B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40188110P 2010-08-20 2010-08-20
US61/401,881 2010-08-20
US201161495055P 2011-06-09 2011-06-09
US61/495,055 2011-06-09
PCT/US2011/048578 WO2012024666A2 (en) 2010-08-20 2011-08-22 Cells expressing th1 characteristics and cytolytic properties

Publications (2)

Publication Number Publication Date
BR112013003989A2 true BR112013003989A2 (pt) 2017-11-14
BR112013003989B1 BR112013003989B1 (pt) 2020-11-24

Family

ID=45594250

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013003989-2A BR112013003989B1 (pt) 2010-08-20 2011-08-22 composição compreendendo células cd4+ th1/assassinas e método in vitro para destruir células cancerosas, células infectadas ou combinações das mesmas

Country Status (18)

Country Link
US (3) US20120045423A1 (pt)
EP (1) EP2606125B1 (pt)
JP (2) JP6408219B2 (pt)
KR (1) KR101900807B1 (pt)
CN (2) CN108245673A (pt)
AU (1) AU2011291477B2 (pt)
BR (1) BR112013003989B1 (pt)
CA (1) CA2808873C (pt)
DK (1) DK2606125T3 (pt)
ES (1) ES2660577T3 (pt)
HU (1) HUE036094T2 (pt)
IL (1) IL224813B (pt)
NO (1) NO2606125T3 (pt)
PL (1) PL2606125T3 (pt)
PT (1) PT2606125T (pt)
SG (2) SG187846A1 (pt)
TR (1) TR201802334T4 (pt)
WO (1) WO2012024666A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2606125T3 (pt) * 2010-08-20 2018-04-21
KR101697473B1 (ko) 2014-11-26 2017-01-18 주식회사 녹십자랩셀 T 세포를 이용한 자연살해세포의 배양방법
ES2753259T3 (es) 2015-04-22 2020-04-07 Curevac Ag Composición que contiene ARN para el tratamiento de enfermedades tumorales
JP7337373B2 (ja) * 2019-07-29 2023-09-04 サイアス株式会社 抗原特異的ｔ細胞の製造方法
US11730313B2 (en) * 2021-02-24 2023-08-22 Kirsten Wilkins Slow cooker liner system with integrated dividers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030050392A1 (en) * 1998-09-22 2003-03-13 Brother Kogyo Kabushiki Kaisha Water-based ink for ink jetting and ink jet recording method
US20030194395A1 (en) * 2001-09-17 2003-10-16 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
US20030134415A1 (en) 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
WO2003024312A2 (en) 2001-09-17 2003-03-27 Valeocyte Therapies Llc Cell therapy system
JP4699755B2 (ja) 2002-08-23 2011-06-15 ガブリエル ムルソフ， 腫瘍細胞におけるアポトーシスのＨｓｐ７０／Ｈｓｐ７０ペプチド依存性誘導物質としてのグランザイムＢの使用
US7435592B2 (en) * 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
US7402431B2 (en) 2004-03-01 2008-07-22 Immunovative Therapies, Ltd. T-cell therapy formulation
DK2573166T3 (da) * 2004-02-26 2016-07-04 Immunovative Therapies Ltd Fremgangsmåder til fremstilling af T-celler til celleterapi
NO2606125T3 (pt) 2010-08-20 2018-04-21

Also Published As

Publication number Publication date
AU2011291477B2 (en) 2016-07-28
HUE036094T2 (hu) 2018-06-28
US20120045423A1 (en) 2012-02-23
JP6525946B2 (ja) 2019-06-05
JP2013536232A (ja) 2013-09-19
DK2606125T3 (en) 2018-03-05
JP2017061558A (ja) 2017-03-30
CA2808873C (en) 2020-02-18
SG10201510524TA (en) 2016-01-28
KR101900807B1 (ko) 2018-11-08
PL2606125T3 (pl) 2018-05-30
US10385315B2 (en) 2019-08-20
WO2012024666A3 (en) 2012-05-18
US20130196428A1 (en) 2013-08-01
EP2606125A2 (en) 2013-06-26
CN103068973A (zh) 2013-04-24
ES2660577T3 (es) 2018-03-23
KR20130103485A (ko) 2013-09-23
US20130195825A1 (en) 2013-08-01
WO2012024666A2 (en) 2012-02-23
SG187846A1 (en) 2013-03-28
EP2606125B1 (en) 2017-11-22
CA2808873A1 (en) 2012-02-23
IL224813B (en) 2020-06-30
TR201802334T4 (tr) 2018-03-21
EP2606125A4 (en) 2014-03-19
NO2606125T3 (pt) 2018-04-21
JP6408219B2 (ja) 2018-10-17
PT2606125T (pt) 2018-02-27
CN108245673A (zh) 2018-07-06
AU2011291477A1 (en) 2013-04-04
BR112013003989B1 (pt) 2020-11-24

Similar Documents

Publication Publication Date Title
CU20200089A7 (es) Moléculas de unión contra bcma
MX2018004146A (es) Células modificadas genéticamente que comprenden un gen mano modificado de la región constante alfa del receptor de células t.
BR112013016914A2 (pt) combinação simbiótica de probióticos e oligossacarídeos do leite humano para promover o crescimento de microbiota benéfica
WO2014186469A3 (en) Human application of engineered chimeric antigen receptor (car) t-cells
BR112013003989A2 (pt) características e propriedades citolíticas de células expressando th1
IN2014DN09782A (pt)
CO7170149A2 (es) Producción mejorada de derivados de ácidos grasos
BR112014015417A8 (pt) diferenciação de células-tronco embrionárias humanas em células positivas de insulina hormonal únicas
BR112013002811A8 (pt) meios básicos simplificados para cultura celular pluripotente de humano
BR112013004514A2 (pt) diferenciação das células-tronco embrionárias humanas
BR112015011158A8 (pt) triazolopirazina, seu uso e preparação farmacêutica
BR112012016376A2 (pt) compostos de pirrolo-aminopirimida substituída
BR112013004616A2 (pt) diferenciação das células tronco embrionárias humanas
MX366912B (es) Producción de vacuna recombinante en e. coli mediante conjugación enzimática.
BR112015008612A2 (pt) métodos de tratamento utilizando adenovirus
WO2012046943A3 (ko) 재조합된 유전자발현 조절서열을 가지는 종양 특이적 발현이 개선된 유전자 전달체
NZ741724A (en) Renal cell populations and uses thereof
BR112014015933A2 (pt) métodos e materiais para reduzir a degradação das proteínas recombinantes
PE20141012A1 (es) Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparacion
BR112015009229A2 (pt) composição tendo como alvo a expressão de genes para plaquetas, célula tronco hematopoiética, uso da referida célula tronco e método in vitro ou ex vivo para gerar uma célula tronco modificada
CO2020006443A2 (es) Métodos y composiciones para la dosificación de células t con receptor de antígeno quimérico alogénicas
UY33417A (es) Formulación que contiene acido azelaico con adición de pigmento
MY170604A (en) Inhibitors of apoptosis and uses thereof
MX2020004063A (es) Sistemas y metodos para producir celulas b modificadas geneticamente para expresar anticuerpos seleccionados.
BR112014017819A8 (pt) Método de produzir células cancerígenas imunogênicas isoladas, células cancerígenas imunogênicas isoladas, composição imunogênica e vacina autóloga de câncer

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/08/2011, OBSERVADAS AS CONDICOES LEGAIS.